|
Volumn 17, Issue 2, 2010, Pages 57-58
|
Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;
BUDESONIDE PLUS FORMOTEROL;
CORTICOSTEROID;
LEUKOTRIENE RECEPTOR BLOCKING AGENT;
LONG ACTING DRUG;
SALMETEROL;
ADD ON THERAPY;
ASTHMA;
CANADA;
CLINICAL TRIAL;
CONSENSUS;
DISEASE CONTROL;
DISEASE EXACERBATION;
DISEASE SEVERITY;
DRUG DOSE INCREASE;
DRUG EFFICACY;
DRUG SAFETY;
DRUG USE;
HEALTH EDUCATION;
HUMAN;
LOW DRUG DOSE;
MEDICAL SOCIETY;
MONOTHERAPY;
NOTE;
PRIORITY JOURNAL;
TREATMENT DURATION;
|
EID: 77953917709
PISSN: 11982241
EISSN: None
Source Type: Journal
DOI: 10.1155/2010/378289 Document Type: Note |
Times cited : (13)
|
References (8)
|